Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

Abstract Background Renal cell carcinomas (RCC) harboring a TFE3 gene fusion (TfRCC) represent an aggressive subset of kidney tumors. Key signaling pathways of TfRCC are unknown and preclinical in vivo data are lacking. We investigated Akt/mTOR pathway activation and the preclinical efficacy of dual...

Full description

Bibliographic Details
Main Authors: Eric C. Kauffman, Martin Lang, Soroush Rais-Bahrami, Gopal N. Gupta, Darmood Wei, Youfeng Yang, Carole Sourbier, Ramaprasad Srinivasan
Format: Article
Language:English
Published: BMC 2019-09-01
Series:BMC Cancer
Subjects:
TFE3
MITF
Translocation renal cell carcinoma
Fusion gene
mTOR inhibitor
AZD8055
Online Access:http://link.springer.com/article/10.1186/s12885-019-6096-0

Internet

http://link.springer.com/article/10.1186/s12885-019-6096-0

Similar Items